Acuta Capital Partners, LLC Verastem, Inc. Transaction History

Acuta Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.02 - $1.83 $812,890 - $1.46 Million	-796,951 Reduced 79.94%	200,000 $232,000
Q1 2022 May 16, 2022	SELL	$1.06 - $2.1 $920,131 - $1.82 Million	-868,049 Reduced 46.54%	996,951 $1.41 Million
Q4 2021 Feb 14, 2022	SELL	$2.05 - $3.2 $314,537 - $490,985	-153,433 Reduced 7.6%	1,865,000 $3.82 Million
Q2 2021 Aug 16, 2021	SELL	$2.57 - $4.85 $706,634 - $1.33 Million	-274,955 Reduced 11.99%	2,018,433 $8.22 Million
Q1 2021 May 17, 2021	SELL	$1.9 - $2.82 $202,562 - $300,645	-106,612 Reduced 4.44%	2,293,388 $5.67 Million
Q3 2020 Nov 16, 2020	SELL	$1.11 - $1.68 $277,500 - $420,000	-250,000 Reduced 9.43%	2,400,000 $2.9 Million
Q2 2020 Aug 14, 2020	SELL	$1.69 - $4.2 $1.81 Million - $4.5 Million	-1,070,930 Reduced 28.78%	2,650,000 $4.56 Million
Q1 2020 May 15, 2020	BUY	$1.26 - $3.38 $4.69 Million - $12.6 Million	3,720,930 New	3,720,930 $9.5 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.09B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.